Xenon is a clinical genetics-based drug development company. Independently and through partnerships with leading global pharmaceutical companies, Xenon identifies and validates new targets for drug development and converts that knowledge into innovative and differentiated medicines. Its programs focus on indications of important unmet medical needs, including pain, anemia, iron overload, metabolic and cardiovascular disease. Xenon’s pipeline of products spans discovery through to Phase 2 clinical trials. The company is headquartered in Burnaby, British Columbia.